Colin advises clients throughout their lifecycle (all the way from start-up/spin-out to multinational listed companies) on the commercialisation of their intellectual property rights. In particular, advising on licensing deals, collaborations and R&D projects, distribution and manufacturing and the IP, commercial and regulatory aspects of M&A, VC investments and IPOs.

Having a 1st class degree in Cell Biology his practice has naturally become focused on the life sciences, healthcare and technology (with a particular focus on med-tech and clean-tech) sectors.

显示完整简历 隐藏完整简历

最新新闻和观点

私募股权

Advising Rutland Partners on JSM Group investment

2021年2月26日

作者

点击此处了解更多
酒店与休闲

Acting on transformational roll-up and $250 million crossover financing of cutting-edge UK and European biotech companies

2021年2月16日

作者 Ross McNaughton 以及 Colin McCall

点击此处了解更多
酒店与休闲

Edison Open House Global Healthcare 2021 – key takeaways from our panel

2021年2月4日
Quick read

作者

点击此处了解更多
pipette
Synapse

Private equity investment in life sciences sector

2020年7月30日
IN-DEPTH ANALYSIS

作者

点击此处了解更多

与我会面: